TABLE 3.
Grazoprevir concn (nM) | Treatment (fold EC50) | Mutations (% population)a |
---|---|---|
No drug | 0 | A61T (100), G90R (5) |
1 | 1 | A61T (100), G90R (5) |
3 | 3 | A61T (100), G90R (5), G162R (5) |
10 | 10 | A61T (70), G90R (5), D168V (30), D168G (30) |
30 | 30 | A61T (95), G90R (5), D168V (50), D168A (50) |
Key amino acid substitutions deduced from population sequencing of resistant colonies and quantified based on peaks from the electropherogram are indicated.